REpeated ASSEssment of SurvivorS in Intracerebral Hemorrhage Study
Launched by JOHNS HOPKINS UNIVERSITY · Nov 3, 2022
Trial Information
Current as of November 14, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
The REASSESS ICH study is an observational, long-term follow-up of people who survived a spontaneous brain bleed (intracerebral hemorrhage, ICH). It asks whether removing the clot with minimally invasive surgery helps reduce later decline in thinking and memory over about 2 years. The study will compare people who had clot evacuation with data from those who received standard care, using a standard battery of cognitive tests and brain-imaging measurements to gauge how much clot was removed.
Eligible participants are survivors who previously took part in the MISTIE III or ENRICH trials. The study aims to enroll about 350 people and is by invitation, across many U.S. sites, led by Johns Hopkins University. It includes adults and children of all genders; there are no listed exclusion criteria. If a participant is no longer living, a relative may be interviewed. Over the 24-month follow-up, participants will have long-term assessments of memory, thinking, daily activities, mood, and quality of life, often conducted by phone. Data will be shared with researchers in a de-identified way after the study ends.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Participants in the study must be survivors enrolled in MISTIE III and ENRICH trials at end of each trial's final follow-up (day 365 in MISTIE III and day 180 in ENRICH). Relatives of known survivors that are found to be deceased since the end of each trial will be interviewed to capture relevant data.
- Exclusion Criteria:
- • None
About Johns Hopkins University
Johns Hopkins University, a prestigious research institution located in Baltimore, Maryland, is renowned for its commitment to advancing medical science and public health through innovative clinical trials. With a rich history of groundbreaking research and a multidisciplinary approach, the university's clinical trial initiatives focus on translating scientific discoveries into effective treatments and interventions. Leveraging state-of-the-art facilities and a collaborative network of experts, Johns Hopkins University conducts rigorous clinical studies that aim to improve patient outcomes and address critical health challenges. Its dedication to ethical standards and participant safety underscores its role as a leader in clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ann Arbor, Michigan, United States
Baltimore, Maryland, United States
Stanford, California, United States
San Antonio, Texas, United States
Detroit, Michigan, United States
Albuquerque, New Mexico, United States
Winston Salem, North Carolina, United States
Nashville, Tennessee, United States
Jacksonville, Florida, United States
Philadelphia, Pennsylvania, United States
Louisville, Kentucky, United States
Baltimore, Maryland, United States
Chicago, Illinois, United States
New Haven, Connecticut, United States
La Jolla, California, United States
Cincinnati, Ohio, United States
Fairway, Kansas, United States
Birmingham, Alabama, United States
Minneapolis, Minnesota, United States
Ann Arbor, Michigan, United States
Sacramento, California, United States
Chicago, Illinois, United States
Saint Louis, Missouri, United States
Piscataway, New Jersey, United States
Bronx, New York, United States
Houston, Texas, United States
Fairfax, Virginia, United States
Patients applied
Trial Officials
Wendy Ziai, MD
Principal Investigator
Johns Hopkins University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials